« Previous - Bortezomib-based regimensNext - Thalidomide-based regimens »

Immunomodulatory drugs (iMIDs) are often used in first-line, non-intensive myeloma treatment regimens. Watch the following video where Dr Charlotte Pawlyn explains how iMIDs work and why they are effective in treating myeloma. There are two iMIDs licensed for use in newly-diagnosed, transplant-ineligible patients: thalidomide and lenalidomide.